



Pécsi Tudományegyetem
1367

PainPatch – Transdermal Patch

Targeted, controlled drug delivery for the local treatment of musculoskeletal pain

CHALLENGE

Acute and chronic musculoskeletal pain is widespread. Long-term use of oral analgesics may cause side effects, while topical products do not always provide controlled, sustained drug delivery.

SOLUTION

A locally acting transdermal patch combining diclofenac and capsaicin. The platform is designed for more consistent delivery, ease of use and flexible dose adjustment.

INVESTMENT HIGHLIGHT

Combining diclofenac and capsaicin, the patch may create a new treatment option through easy application, more consistent local drug delivery and adjustable dosing.

PARTNERSHIP OPPORTUNITY

We are seeking a pharmaceutical development and commercialization partner for clinical and regulatory advancement, manufacturing scale-up, market-entry strategy and commercial exploitation of the technology.

Investment need: 2 M USD

THE TEAM



Dr. Erika Pintér
PainPatch Ltd. –CEO



Dr. Zsuzsanna Helyes
PainPatch Ltd. –Founder



Dr. Szabolcs László
Technology expert



Dr. Gábor Pozsgai
Research Co-ordinator



Dr. Ödön Wagner
Technology Expert



Dr. Lajos Botz
Clinical Trials Expert



Tradíció & Innováció



painpatchkft@gmail.com



Targeted local application

Laboratory prototype development



TRL 7 TARGET

TECHNOLOGY READINESS

TARGET MARKET

PAIN MANAGEMENT

IP STRATEGY
PATENT
POTENTIAL

JAN 2027
PROJECT
COMPLETION

6 PROTOTYPES
SHORT-TERM
STABILITY TESTING

HUF 95.7M
GRANT FUNDING
AWARDED

MVP +
PROTOTYPE
BY PROJECT
COMPLETION

DUAL-ACTIVE
PATCH
DICLOFENAC +
CAPSAICIN